Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06673459

BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients

Busulfan Plus Cyclophosphamide Vs. Total Body Irradiation Plus Cyclophosphamide for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute T Lymphoblastic Leukemia: a Randomized Controlled, Open-label, Multi-center Clinical Trial

Sponsor: Anhui Provincial Hospital

Conditions ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Chemotherapy T-Cell Lymphocytic Leukemia Total Body Irradiation

Interventions BuCy TBICy

Updated 3 times since 2024 Last updated: Nov 2, 2024 Started: Dec 1, 2024 Primary completion: Nov 30, 2029 Completion: Nov 30, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION and Chemotherapy, this trial is actively recruiting participants. The trial is conducted by Anhui Provincial Hospital and has accumulated 3 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE3
Dec 2024 — Aug 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anhui Provincial Hospital
Children's Hospital of Soochow University
First Affiliated Hospital Xi'an Jiaotong University
Fujian Medical University Union Hospital
Nanfang Hospital, Southern Medical University
Ruijin Hospital
The First Affiliated Hospital of Soochow University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Zhejiang University

Data source: The First Affiliated Hospital of Soochow University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suzhou, China